SGLT-2 inhibitors and DKA

Sdílet
Vložit
  • čas přidán 30. 09. 2020

Komentáře • 12

  • @staciegulizia4144
    @staciegulizia4144 Před 2 lety +2

    Thank you for educating people about EDKA. I almost lost my husband to this last week. He had no symptoms until he passed out. It was caused by his low carb diet mixed with the prescribe Jardiance. Thankfully, the ER doctor diagnosed it correctly and the ICU administered the correct treatment. They discontinued the Jardiance.

    • @saxgirlhornboy6458
      @saxgirlhornboy6458 Před rokem

      Hooray!
      What was his glucose level, and what treatment did he receive?

    • @StarvingMyselfToLIFE
      @StarvingMyselfToLIFE Před 4 měsíci

      Could the problem been the Jardiance alone, since many people seem to thrive on low carb diets for a long time

  • @ansonma7351
    @ansonma7351 Před 2 lety

    This is very good thankyou

  • @StarvingMyselfToLIFE
    @StarvingMyselfToLIFE Před 4 měsíci

    Exactly what issue are SGLT2's attempting to resolve?

  • @Psychiatrist78
    @Psychiatrist78 Před rokem

    Actually they do have increased urination and thirst.( that is the basic side effect of sglt-2 inhibtors)

  • @drnaeeem5422
    @drnaeeem5422 Před 3 lety

    Does they increase the risk....???

    • @im_pharm_appe1992
      @im_pharm_appe1992  Před 2 lety

      The risk of euglycemic DKA is increased with theses agents, but if patient selection and education on management of use of SGLT-2-I during illness or around the time of surgery the risk can be reduced.

  • @oswaldfernandes8266
    @oswaldfernandes8266 Před 3 lety

    Dka due to sglt2 inhibitors are easy target to the covid virus because the immune system is suppressed because of the acidosis and the drug has to be treated with caution in this covid pandemic.

    • @im_pharm_appe1992
      @im_pharm_appe1992  Před 2 lety

      At this time the same level of caution in selecting the ideal candidate for the drug therapy remains in order to reduce the risk of euglycemic DKA. Patients may have slight enhancement of infection due to side-effects of DKA, but no different than DKA in type-1 DM using insulin.